Ketamine Therapy Eligibility: Do You Need a Diagnosis?

What Is Ketamine Therapy?

Ketamine is a medication that has been FDA-approved as an anesthetic since 1970 and has been on the WHO List of Essential Medicines since 1985.¹ In sub-anesthetic, provider-determined doses, it is prescribed off-label for psychiatric conditions including depression, anxiety, and PTSD. Ketamine (the generic compound) and Spravato (esketamine nasal spray) are distinct products with different regulatory pathways. Spravato holds a separate FDA approval for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program.²

Because it works through NMDA pathways, ketamine temporarily modulates glutamate signaling and promotes neuroplasticity.³ The medicine enables the brain to form new neural connections, which is fundamentally different from traditional antidepressants that target serotonin or norepinephrine. Rapid symptom improvement, often within hours or days of the first session, is a well-documented characteristic of ketamine therapy. More durable benefits develop over a series of treatments.

The main delivery routes include:

• IV infusion: Administered intravenously in a medical office.
• Sublingual tablet: Held in the mouth and completed at home.
• Subcutaneous injection: Administered just under the skin at home.
• Spravato nasal spray: Administered in a certified healthcare office.

Ketamine has a well-established evidence base, and for many people the key questions are whether they qualify and which delivery model fits their needs.

Do You Need a Diagnosis for Ketamine Therapy?

A qualifying diagnosis is required before a provider can prescribe ketamine, but you do not need to arrive with a pre-existing diagnosis from another doctor. The clinician who evaluates you for ketamine therapy can assess your symptoms and establish a qualifying diagnosis during the intake consultation. The rest of the section unpacks what that means for your care.

Yes, a Diagnosis Is Required, but the Type Matters

A "qualifying diagnosis" means a provider has determined that you meet diagnostic criteria for a condition that ketamine therapy can appropriately treat. Standard medical requirements for any prescription medication mandate an evaluation, and ketamine is no exception.

Distinguishing between a formal diagnosis and a working or provisional diagnosis helps clarify the process. A formal diagnosis is documented by a psychiatrist or primary care provider in your medical record, often with standardized assessments like the PHQ-9 or GAD-7. During an initial medical evaluation, a provider may establish a provisional diagnosis when a patient presents with clear symptom patterns but has not previously been formally diagnosed. Both are valid bases for prescribing. The diagnosis must be made by a licensed professional, but that person can be the one you see through a ketamine therapy program.

If you have never been formally diagnosed but suspect you are experiencing depression, anxiety, or PTSD, that does not disqualify you. The intake appointment is exactly where your diagnosis gets established.

Formal Diagnosis vs. Provisional Diagnosis

A formal diagnosis typically comes from a psychiatrist, psychologist, or primary care provider after a clinical interview and validated assessment tools. When a provider identifies symptom patterns consistent with a condition during an initial evaluation, they can establish a provisional or working diagnosis, even if the patient has no prior diagnostic history.

Provisional diagnoses are routine in everyday practice. Many adults experiencing depression or anxiety have never received a formal diagnosis because they have not previously sought psychiatric care. A licensed provider conducting a ketamine therapy intake can review symptom history, administer validated screening instruments, and determine whether the patient meets criteria — direct assessment is standard practice, not a workaround.

Whether your diagnosis is longstanding or newly established during intake, the standard remains the same: a licensed provider must confirm your symptoms meet criteria for a condition ketamine can appropriately treat.

• Formal diagnosis: Documented by a prior provider, often with standardized instruments, and part of an existing treatment record.
• Provisional diagnosis: Established during the ketamine program's intake evaluation based on symptom presentation and an interview.

How Telehealth Providers Establish a Qualifying Diagnosis

Telehealth ketamine programs conduct medical evaluations via video consultation with licensed professionals, such as psychiatrists or psychiatric nurse practitioners. Video evaluations serve the same function as an in-person psychiatric intake.

Your evaluation typically includes a review of mental health history, current symptoms, prior treatments, current medications, and medical history screening for contraindications. The provider uses the gathered information alongside standardized screening tools to determine whether a treatable condition is present and whether ketamine therapy is medically appropriate. Unlike Spravato, which requires a pre-existing treatment-resistant depression (TRD) diagnosis and documented failed antidepressant trials (detailed below), off-label ketamine prescribed through telehealth does not carry the same prerequisite.

Expect a thorough medical assessment, not a formality. The appointment is where eligibility is determined, the diagnosis is confirmed or established, and the treatment plan is personalized.

What if You Suspect a Condition but Have Not Been Formally Diagnosed?

If you recognize your own symptoms but have not yet seen a mental health provider, you are not excluded from pursuing ketamine therapy. Barriers to psychiatric care — cost, wait times, stigma — mean many adults live with undiagnosed depression, anxiety, or PTSD.

Ketamine intake consultations exist precisely for such scenarios. You do not need to first see a separate psychiatrist, obtain a formal diagnosis, and then bring documentation to a ketamine provider. The evaluating specialist will assess your symptoms directly.

Be prepared to discuss:

• How long you have been experiencing symptoms.
• How your symptoms affect your daily functioning.
• Any prior treatment, including therapy or medication.
• Your specific goals for treatment.

Suspecting you have a condition is a valid reason to seek evaluation, and the intake consultation described above is where that determination happens.

What Conditions and Diagnoses Qualify You for Ketamine Therapy?

The conditions that qualify someone for ketamine therapy depend on the specific program, delivery method, and care setting. Below is a breakdown of the major categories.

FDA-Approved Use: Spravato (Esketamine) for Treatment-Resistant Depression

Spravato is the brand name for esketamine nasal spray, the only ketamine-derived product with FDA approval for a mental health indication. The medication is approved specifically for treatment-resistant depression and for major depressive disorder with acute suicidal ideation or behavior.

Because of its FDA-approved status, Spravato carries specific regulatory requirements. The nasal spray must be administered in a certified healthcare setting under the REMS program, with in-office monitoring for at least two hours after each dose.² Patients must have a documented history of failed antidepressant trials, specifically at least two different antidepressants at adequate dose and duration. The REMS requirement creates a higher diagnostic and documentation bar than off-label ketamine programs require.

Spravato is one pathway with its own eligibility criteria and delivery constraints. The nasal spray is not the only way to access ketamine-based treatment, and its FDA approval reflects regulatory status rather than superiority over other ketamine formulations.

Common Off-Label Uses: Depression, Anxiety, PTSD, and OCD

Off-label prescribing, in which a licensed provider prescribes an FDA-approved medication for a condition not specified on its original label, is a widespread, legally accepted practice across all specialties. Approximately 20% of all U.S. prescriptions are off-label, and psychiatry specifically runs higher.⁴

For ketamine, the most common off-label psychiatric applications include major depressive disorder, generalized anxiety disorder, social anxiety disorder, PTSD, and OCD.

• Depression: In Mindbloom's published real-world outcomes study, 89% of clients reported symptom improvement for depression, with response rates of 56–63%.⁵
• Anxiety: In Mindbloom's published real-world outcomes study, 89% of clients reported symptom improvement for anxiety.⁶
• PTSD: In Mindbloom's published outcomes data, 92% of clients reported symptom improvement for PTSD.⁷
• OCD: A smaller but growing evidence base supports ketamine therapy for OCD, with published studies showing symptom reduction.⁸

Off-label prescribing is how the majority of ketamine therapy is delivered for mental health.

Chronic Pain Pathways

Ketamine has a long history of use in pain management, separate from its mental health applications. Some clinics and pain specialists prescribe ketamine infusions or compounded formulations for chronic pain conditions including complex regional pain syndrome (CRPS), neuropathic pain, fibromyalgia, and certain migraine disorders.

Chronic pain programs typically operate through in-clinic infusion centers and involve different dosing protocols, treatment durations, and oversight structures than mental health programs. The qualifying diagnosis for pain-focused ketamine is a documented chronic pain condition, often after other pain management approaches have been tried.

Psychiatric and chronic pain indications are distinct care pathways with different eligibility criteria, delivery models, and evidence bases. The current article focuses on psychiatric applications. If you are seeking ketamine for chronic pain, look for practitioners who specialize in pain management protocols.

What At-Home Ketamine Treats vs. In-Clinic Infusion

At-home ketamine programs and in-clinic infusion centers treat many of the same conditions but differ in delivery method, setting, and care model. At-home programs typically use sublingual tablets or subcutaneous injection under remote supervision. In-clinic programs administer IV infusions or intramuscular injections with on-site medical staff.

At-home programs like Mindbloom most commonly treat depression, anxiety, and PTSD through multi-session programs with integrated therapeutic support. In-clinic infusion centers may also treat chronic pain conditions and may offer single-session or short-course options. The key differentiator is not which conditions can be treated, but the care model surrounding the treatment. At-home programs emphasize preparation, integration, and programmatic support, while some infusion centers focus primarily on medication administration.

Both settings can deliver effective ketamine therapy; the right choice depends on your medical needs, preferences, and the level of therapeutic support you want.

Comorbid Conditions That Often Improve Alongside the Primary Diagnosis

Comorbid conditions co-occur with a primary diagnosis. Many people seeking ketamine therapy for depression, anxiety, or PTSD also experience adjacent conditions that affect their quality of life. Eligibility hinges on the primary diagnosis. Comorbid and adjacent conditions are part of why people pursue treatment and part of what often improves alongside it.

The following conditions frequently overlap with primary diagnoses:

• Burnout: Chronic occupational stress that overlaps with depressive symptoms. Burnout is not a standalone DSM-5 diagnosis but frequently co-occurs with depression or anxiety.
• Grief: Prolonged or complicated grief can meet criteria for prolonged grief disorder and often co-occurs with major depression.
• Postpartum depression: A specific presentation of major depressive disorder occurring after childbirth. Eligibility for ketamine during the postpartum period depends on a medical evaluation, including breastfeeding status.
• ADHD: Frequently co-occurs with depression and anxiety. Ketamine is not prescribed for ADHD itself, but treating the co-occurring mood or anxiety disorder may improve overall functioning.
• OCD: Can be a primary qualifying diagnosis in some programs. In others, OCD improves alongside treatment of co-occurring depression or anxiety.
• Substance use: Active substance use disorders are often a contraindication, but some individuals with a history of substance use in stable recovery may qualify. A medical evaluation determines appropriateness.
• Migraines: Some people with depression or anxiety also experience migraines, which may improve as overall stress and mood improve. For migraines as a primary concern, a pain-focused ketamine pathway may be more appropriate.

Your qualifying diagnosis opens the door to treatment. The broader constellation of symptoms and conditions you are experiencing is part of what your provider evaluates and part of what may improve over the course of a treatment program.

Who Can Prescribe and Deliver Ketamine Therapy?

Several types of licensed professionals can prescribe and oversee ketamine therapy, and knowing the differences helps you evaluate where to receive care.

Can Any Doctor Prescribe Ketamine?

Ketamine is a Schedule III controlled substance, meaning any licensed physician (MD or DO) with DEA registration can legally prescribe it off-label for mental health conditions. Prescribing authority is not limited to psychiatrists.

In practice, the professionals who most commonly prescribe ketamine for mood and anxiety disorders include psychiatrists, anesthesiologists, emergency medicine physicians, and advanced practice providers operating under appropriate licensure. The legal authority to prescribe is broad, but medical expertise matters. A provider's experience with ketamine therapy, psychiatric assessment, and ongoing patient monitoring is more relevant than their specific specialty title.

Choosing ketamine should be a collaborative decision with your prescriber. The question is not whether a doctor can prescribe ketamine, but whether they have the training and protocols to do so safely and effectively for your specific condition.

Psychiatrists, Anesthesiologists, and Psychiatric NPs

Three professional types are most commonly involved in prescribing ketamine for mood and anxiety disorders. Each brings different training and strengths.

• Psychiatrists: Specialize in diagnosing and treating mental health conditions. They bring deep expertise in psychiatric assessment, medication management, and understanding ketamine therapy drug interactions.
• Anesthesiologists: Have extensive training in ketamine pharmacology, airway management, and hemodynamic monitoring. They are most commonly found in IV infusion clinic settings.
• Psychiatric nurse practitioners (NPs): Licensed advanced practice providers with specialized psychiatric training. In many states, they have independent prescribing authority for controlled substances and frequently evaluate clients in telehealth programs.

All three are qualified to prescribe and oversee ketamine therapy. The best fit depends on the delivery setting and your medical needs.

In-Clinic Infusion vs. At-Home Oral and Injectable Programs

In-clinic infusion programs administer ketamine intravenously in a medical office, typically with on-site nursing staff and vital sign monitoring. At-home programs prescribe sublingual tablets or subcutaneous injections that clients self-administer in their own home with a required peer treatment monitor present and remote oversight.

• In-clinic IV: Highest bioavailability, immediate onset, and on-site medical staff. Sessions typically require travel to a clinic, scheduling during business hours, and higher per-session cost. Some people prefer the in-person environment and direct medical supervision.
• At-home sublingual: Needle-free, administered by holding a tablet between the cheek and gum. Effects begin within 10 to 15 minutes. Session intensity can vary somewhat between sessions. Sublingual administration is suited to people who value comfort, privacy, and the therapeutic benefits of a familiar environment.
• At-home subcutaneous: Administered via a small insulin needle into the abdomen. Effects begin in about 5 minutes. Subcutaneous delivery offers higher bioavailability and more consistent session intensity than sublingual tablets. Mindbloom is the only at-home provider offering subcutaneous administration.

Different care approaches exist for different needs and preferences. The delivery method does not determine treatment quality; the protocols, screening, and support surrounding the treatment do.

Credentials and Licensing to Look For

When evaluating a ketamine therapy program, certain credentials and structural features signal legitimacy and patient safety.

• Licensed prescriber: The evaluating and prescribing professional should be a licensed MD, DO, NP, or PA with active state licensure and DEA registration.
• Comprehensive screening protocol: The provider should conduct a medical and psychiatric evaluation before prescribing, not just a brief questionnaire.
• Ongoing oversight: Treatment should include follow-up consultations, not just an initial prescription. Dosing adjustments, progress monitoring, and safety check-ins should be part of the program.
• Published outcomes or data: Programs that publish peer-reviewed research on their protocols demonstrate accountability and transparency.
• Integration support: Programs that include preparation and integration support more durable outcomes.
• Clear safety protocols: Ask about emergency procedures, contraindication screening, and what happens if you experience an adverse event.

Credentials and protocols matter more than marketing. A legitimate program will welcome your questions about its care framework.

Medical Eligibility: Who Should Not Try Ketamine Therapy?

Eligibility is determined through the screening process described above. Certain medical and psychiatric conditions may make ketamine therapy inappropriate or require additional evaluation before treatment can proceed.

Ketamine therapy may not be appropriate for individuals with:

• Uncontrolled hypertension: Ketamine can temporarily increase blood pressure and heart rate. Individuals with uncontrolled hypertension may not be appropriate candidates, which is why cardiovascular screening is part of the intake process.
• Active psychotic disorders: Ketamine's dissociative properties may exacerbate psychotic symptoms in conditions like schizophrenia or schizoaffective disorder.
• Active substance use disorders: Active, unstable substance use may increase risk and complicate treatment. Individuals in stable recovery may still qualify depending on a medical evaluation. Abuse and dependence risk in supervised, sub-anesthetic protocols is low.
• Pregnancy or breastfeeding: Insufficient safety data exists for ketamine use during pregnancy or lactation.
• Certain cardiovascular conditions: Serious heart or breathing problems require careful evaluation.
• Unstable mania or bipolar disorder in active manic phase: May require stabilization before ketamine therapy is considered.

Eligibility is an individualized assessment, not a binary checklist. Some conditions that might seem disqualifying can be managed or may not apply in your specific case.

If you are unsure whether a specific condition affects your eligibility, the most reliable step is to complete an intake consultation. Your prescriber will determine whether ketamine therapy is safe and appropriate based on your individual circumstances.

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.